News for Industry
Insurers In Japan Will Soon Offer Coverage to Cell-Cultivating Companies (Live Insurance News)
(Tokyo, Japan) The non-life insurance companies in Japan will begin to sell policies to cover the cultivation of stem cells for regenerative medicine procedures.
Accurexa Announces License For UCSF Brain Stem Cell Device (Bay Street)
(San Francisco, CA) The University of California, San Francisco announced that it has entered into an exclusive license agreement with Accurexa, Inc for global licensing of a medical stereotactic device.
BioTime’s Cell Cure Neurosciences Ltd. Demonstrates Safety and Efficacy of OpRegen® in Animal Studies (Market Watch)
(Alameda, CA) BioTime Inc. completed a series of extensive preclinical safety and efficacy studies for its product OpRegen intended for treatment of dry age-related macular degeneration.
New Stem Cell Bio Drug for Bone Regeneration To Be Released in January (Miami Today News)
(Miami, FL) An adult bone marrow isolated multi-lineage inducible cell called the Miami cell.
Pluristem Pursues Development Strategy in Japan Where New Law Accelerates Path to Market (CNN)
(Haifa, Israel) Pluristem Therapeutics Inc. a leading developer of placenta-based cell therapy products is evaluating strategic opportunities to co-develop and commercialize cell therapy products in Japan.
Scientists Create Therapy-Grade Stem Cells Using New Cocktail to Reprogram Adult Cells (Phys)
(Jerusalem, Israel) Researchers at the Hebrew University of Jerusalem have developed a new formulation that is highly effective in transforming adult stem cells into quality pluripotent stem cells.
Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% Annually (BCC Research)
(Wellesley, MA) BCC research reveals that the global market for stem cells is expected to grow to nearly $10.6 billion by the year 2018.
Cleveland BioLabs Announces Approval to Start Phase 1 Study for Hematopoietic Stem Cell Mobilizer in Russian Federation (Market Wired)
(Buffalo, NY) Cleveland BioLabs Inc. receive approval from the Russian Ministry of health to begin phase 1 clinical trials for the induction and mobilization of hematopoietic stem cells.
Medipost America Clears Phase For IND Stem Cell Clinical Trial (Business Wire)
(Rockville, MD) MEDIPOST America Inc. announced US FDA approval of a phase 1/2 clinical trial for PNEUMOSTEM for newborn infants who will be at high risk for developing bronchopulmonary dysplasia (BPD).